+39.4%
GM vs MRNA
+945.0%
-905.6%
-16.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.6% | +13.1% | -8.5% | +4.4% |
| 7D | +12.1% | +20.6% | -8.6% | +11.7% |
| 30D | +15.2% | +27.1% | -11.9% | +14.7% |
| 3M | +4.9% | +353.4% | -348.5% | +0.2% |
| 6M | +22.6% | +446.3% | -423.6% | +13.1% |
| YTD | +14.4% | +776.2% | -761.7% | +1.3% |
| 1Y | +39.4% | +987.9% | -948.5% | +18.8% |
| All | +39.4% | +945.0% | -905.6% | +18.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling